ClinicalTrials.gg
CompletedNCT00639483Updated Mar 16, 2009

Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

A Phase 2 interventional study of Celecoxib and Placebo in Schizophrenia, sponsored by Pfizer. Completed at 17 sites in 6 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2009-03-16.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Schizophrenia by Pfizer — none open to participants now, none under way, none of them phase 3. Schizophrenia · Pfizer.

Enrollment
5th of 34
270 · median 40
Started
2003
the only one that year
Phase 2
10 of 35
none open now
Registered
20th of 35
by date

Among the 35 studies in Schizophrenia by Pfizer, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2003, is one of 10 in phase 2, and was the 20th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 35 studies in Schizophrenia by Pfizer is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Schizophrenia by Pfizer as a file.
02

Study summary

To assess the efficacy and safety of celecoxib as add-on therapy to risperidone versus risperidone alone in patients with schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia (according to [DSM]-IV-TR criteria and made by a specialist in psychiatry) and acute exacerbation of schizophrenia requiring hospitalization
  • Total PANSS score of ?60 at screening
  • History of schizophrenia of ?10 years (from onset of prodromal symptoms)

Exclusion criteria

Exclusion criteria:

  • Axis-I diagnosis other than schizophrenia
  • Less than a full cycle has lapsed at time of screening following the last injection of a depot antipsychotic
  • Currently taking celecoxib or other selective cyclo-oxygenase 2 inhibitors, or other antiinflammatory medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    A

    Drug: Celecoxib

  • Placebo comparator
    B

    Drug: Placebo

Interventions

  • 200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks

  • DrugPlacebo

    Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score

    Time frame: Week 11

Secondary outcomes

  1. Patient-Reported Outcomes using Treatment Satisfaction Questionnaire for Medication

    Time frame: Week 4 and 11

  2. Physical examination

    Time frame: Week 11

  3. Laboratory exams

    Time frame: Weeks 1, 2, 4, 6, 8, 11

  4. Change from baseline in Global Improvement and Efficacy Index scores of Clinical Global Impressions scale of Psychosis

    Time frame: Weeks 4, 6, and 11

  5. Change from baseline in total PANSS score

    Time frame: Weeks 4 and 6

  6. Change from baseline in PANSS-derived Brief Psychiatric Rating Scale score

    Time frame: Weeks 4, 6, and 11

  7. Change from baseline in combined PANSS Negative plus General Psychopathology Subscale Score and the separate PANSS Psychopathology Subscale Scores

    Time frame: Weeks 4, 6, and 11

  8. Change from baseline in PANSS five-factor component scores

    Time frame: Weeks 4, 6, and 11

  9. Time to onset of clinically meaningful improvement in total PANSS score

    Time frame: Weeks 1, 2, 4, 6, 8, and 11

  10. Adverse events

    Time frame: Weeks 1, 2, 4, 6, 8, 11

07

Study locations

17 sites
  • Pfizer Investigational Site
    La Plata, Buenos Aires (1900), Argentina
  • Pfizer Investigational Site
    Lanús, Buenos Aires 1824, Argentina
  • Pfizer Investigational Site
    La Plata, Pcia. de Buenos Aires 1900, Argentina
  • Pfizer Investigational Site
    Salvador, BA 40325-090, Brazil
  • Pfizer Investigational Site
    PR, Curitiba 80520-000, Brazil
  • Pfizer Investigational Site
    Aparecida de Goiania, Goiania 74922-810, Brazil
  • Pfizer Investigational Site
    Rio De Janeiro, 21944-970, Brazil
  • Pfizer Investigational Site
    Sao Paulo, Brazil
  • Pfizer Investigational Site
    Bonn, 53105, Germany
  • Pfizer Investigational Site
    Muenchen, 80336, Germany
  • Pfizer Investigational Site
    Muenchen, 81675, Germany
  • Pfizer Investigational Site
    Munster, Germany
  • Pfizer Investigational Site
    Mexico City, CP-14370, Mexico
  • Pfizer Investigational Site
    Mandaluyong City, 1550, Philippines
  • Pfizer Investigational Site
    Pasig City, Philippines
  • Pfizer Investigational Site
    Niao-Sung Hsiang, Kaohsiung, Taiwan
  • Pfizer Investigational Site
    Taipei, Taiwan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2008
First posted
Mar 20, 2008
Start
Mar 2003
CompletionActual
Jan 2004
Last update
Mar 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00639483
Lead sponsor
Pfizer
First posted
Mar 20, 2008
Start date
Mar 2003
Completion
Jan 2004
Last update
Mar 16, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion